All In MedTech

FDA Clearance Tracker · P970003-S207

VNS THERAPY SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 23, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 23, 2017

Approved

Time to decision

218 days

Received Nov 17, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P970003-S207
Device name
VNS THERAPY SYSTEM
Applicant location
Houston, TX
Received
Nov 17, 2016
Decided
Jun 23, 2017
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P970003

Device type

Device class
Class III

Every decision under product code LYJ

FDA's approval statement

As written in FDA's record.

Approval for the VNS Therapy System. The device is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.

Source documents

Other decisions for LivaNova USA, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.